Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page
- Check6 days agoChange DetectedAdded a new Study Status entry on 2026-04-03 for revision v3.5.2. Removed the older v3.5.0 revision on 2026-03-02.SummaryDifference0.4%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedA new revision entry v3.5.0 was added to the history. The previous revision v3.4.3 was removed from the list.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision log updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check49 days agoChange DetectedThe Record History page now includes a Study Status section with new entries on 2026-02-27 and 2026-03-02. The 2026-01-26 entry was removed.SummaryDifference0.3%

- Check70 days agoChange DetectedVersion history shows a new Revision: v3.4.2 added, and the funding-status notice along with Revision: v3.4.1 removed. These changes are limited to system-wide versioning and notices and do not modify study data or record content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check78 days agoChange DetectedAdded a site-wide notice about potential data delays due to government funding issues and updated the page version to v3.4.1. Removed the previous v3.4.0.SummaryDifference0.6%

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.